Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Orange you glad you ate that? study tests fruit against fatty liver

NCT ID NCT05558592

Disease control Sponsor: Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether eating 400 grams of fresh oranges daily for a month could improve metabolism in 60 adults with metabolic-associated fatty liver disease (MAFLD). Participants either ate oranges or other fruits. Researchers measured changes in liver fat and blood fats. The goal was to see if oranges could help control the disease.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
oranges (Navelina variety)
What this could lead to
If it works, this could point toward a simple dietary addition to help manage fatty liver disease and reduce metabolic risk.
What could go wrong
This is a small, completed study with only 60 participants. The results may not apply to everyone, and dietary changes alone may not be enough for significant improvement.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

60 people

The number who actually took part.

Started

Mar 2023

Finished

Dec 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * age \> 30 years and \<65 years * diagnosis of MAFLD on the basis of clinical and instrumental parameters Exclusion Criteria: * gastroesophageal reflux diseases; * inflammatory bowel diseases; oncological diseases; * serious medical conditions that may impair participation in the trial; * people who follow a special diet or who use anticoagulants; * subjects unable to follow a diet for religious or other reasons.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Fatty liver, nonalcoholic are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

metabolic disease metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Fatty liver, nonalcoholic Metabolic disease

Contacts and locations

Locations

  • IRCCS Saverio de Bellis

    Castellana Grotte, BARI, 70013, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.